Opus Genetics officer has 3,390 shares withheld

Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation.

Rhea-AI Filing Summary

Opus Genetics, Inc. officer Amy Zaremba Rabourn, Head of Financial Quality Assurance, reported an automatic share withholding related to equity compensation. On January 18, 2026, 3,390 shares of common stock were withheld by the company at a value of $2.10 per share to cover tax obligations from the vesting and settlement of a restricted stock unit award. After this withholding, she beneficially owned 106,628 shares of Opus Genetics common stock directly. The footnote clarifies this was not an open market sale of securities but a tax-related withholding by the issuer.

Insider Trade Summary

Exercise Price or Tax Liability: 3,390 shares

Exercise Price or Tax Liability 1 txn

Insider Zaremba Rabourn Amy

Role Head of Fin. Quality Assurance

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	3,390	$2.10	$7K

Holdings After Transaction: Common Stock — 106,628 shares (Direct)

Footnotes (1)

1. F1. The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Opus Genetics (IRD) report for Amy Zaremba Rabourn?

The filing reports that Opus Genetics officer Amy Zaremba Rabourn had 3,390 shares of common stock withheld by the company on January 18, 2026 to cover tax withholding obligations from a restricted stock unit vesting event.

Was the IRD insider transaction an open market sale of Opus Genetics stock?

No. The footnote explains that the 3,390 shares were withheld by the issuer to satisfy tax withholding obligations from an RSU vesting and were not an open market sale of securities.

How many Opus Genetics (IRD) shares does Amy Zaremba Rabourn own after the reported transaction?

Following the tax-related share withholding, Amy Zaremba Rabourn beneficially owned 106,628 shares of Opus Genetics, Inc. common stock directly.

What was the price used for the Opus Genetics (IRD) share withholding?

The 3,390 shares withheld to cover taxes were valued at $2.10 per share, as shown in the Form 4 transaction details.

What position does the reporting person hold at Opus Genetics (IRD)?

The reporting person, Amy Zaremba Rabourn, is an officer of Opus Genetics, serving as Head of Financial Quality Assurance.

What is the transaction code used in the Opus Genetics (IRD) Form 4 filing?

The Form 4 uses transaction code "F", which in this context indicates shares withheld by the issuer to satisfy tax withholding obligations arising from an equity award vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zaremba Rabourn Amy

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Fin. Quality Assurance

3. Date of Earliest Transaction (Month/Day/Year)
01/18/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/18/2026		F(1)		3,390	D	$2.1	106,628	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities.

	/s/ Amy Rabourn	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.